<DrugInformationSummary id="CDR0000502211"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Trastuzumab works by binding to HER2, a protein found in high levels on some cancer cells and causes them to grow. Trastuzumab blocks the activity of HER2 and triggers a type of immune reaction that kills cells that have a lot of HER2. It is a type of targeted therapy drug called a monoclonal antibody.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab">Trastuzumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000042265">trastuzumab</TerminologyLink><GlossaryLink ref="CDR0000045439">trastuzumab</GlossaryLink><USBrandNames><USBrandName>Herceptin</USBrandName><USBrandName>Hercessi</USBrandName><USBrandName>Herzuma</USBrandName><USBrandName>Kanjinti</USBrandName><USBrandName>Ogivri</USBrandName><USBrandName>Ontruzant</USBrandName><USBrandName>Trazimera</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>tras-TOO-zoo-mab</TermPronunciation><MediaLink ref="CDR0000705467" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000705466" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Trastuzumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Trastuzumab is approved to be used alone or with other drugs to treat:</Para><ItemizedList Style="bullet" id="_5"><ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000737998" dictionary="Cancer.gov" audience="Patient">HER2 positive</GlossaryTermRef> (HER2+).  It is used in patients with:<ItemizedList Style="bullet" id="_6"><ListItem><GlossaryTermRef href="CDR0000788033" dictionary="Cancer.gov" audience="Patient">Hormone receptor-negative</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045079" dictionary="Cancer.gov" audience="Patient">high-risk</GlossaryTermRef> cancer.  It is given:<ItemizedList Style="bullet" id="_7"><ListItem>as <GlossaryTermRef href="CDR0000688810" dictionary="Cancer.gov" audience="Patient">combination therapy</GlossaryTermRef> with:<ItemizedList Style="bullet" id="_8"><ListItem><GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin hydrochloride</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, and either <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045382" dictionary="Cancer.gov" audience="Patient">docetaxel</GlossaryTermRef>; or</ListItem><ListItem>docetaxel and <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef></ListItem></ItemizedList></ListItem><ListItem>alone after combination therapy that included <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef></ListItem></ItemizedList> </ListItem><ListItem><GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">Metastatic</GlossaryTermRef> cancer. It is given:<ItemizedList Style="bullet" id="_9"><ListItem>with paclitaxel as  <GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line treatment</GlossaryTermRef> for metastatic cancer; or</ListItem><ListItem>alone in patients who have received at least one chemotherapy treatment for metastatic cancer</ListItem></ItemizedList></ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445087" dictionary="Cancer.gov" audience="Patient">Stomach</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef></Strong> or <Strong><GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> adenocarcinoma</Strong> (a rare type of <GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">esophageal cancer</GlossaryTermRef>) that has metastasized. It is given: <ItemizedList Style="bullet" id="_12"><ListItem>with <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> and either <GlossaryTermRef href="CDR0000045565" dictionary="Cancer.gov" audience="Patient">capecitabine</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046090" dictionary="Cancer.gov" audience="Patient">fluorouracil</GlossaryTermRef> in patients whose cancer is HER2+</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_11">Trastuzumab is also available in three different forms, <GlossaryTermRef href="CDR0000797117" dictionary="Cancer.gov" audience="Patient">trastuzumab and hyaluronidase-oysk</GlossaryTermRef>, <GlossaryTermRef href="CDR0000801883" dictionary="Cancer.gov" audience="Patient">pertuzumab, trastuzumab, and hyaluronidase-zzxf</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000747093" dictionary="Cancer.gov" audience="Patient">ado-trastuzumab emtansine</GlossaryTermRef>. For more information, see the Drug Information Summaries for <DrugRef href="CDR0000797206" url="/about-cancer/treatment/drugs/trastuzumabandhyaluronidase-oysk">Trastuzumab and Hyaluronidase-oysk</DrugRef>, <DrugRef href="CDR0000801930" url="/about-cancer/treatment/drugs/pertuzumabtrastuzumabandhyaluronidase-zzxf">Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</DrugRef>, and <DrugRef href="CDR0000746946" url="/about-cancer/treatment/drugs/ado-trastuzumab-emtansine">Ado-Trastuzumab Emtansine</DrugRef>.</Para><Para id="_3">Trastuzumab is also being studied in the treatment of other types of cancer.</Para>                          
 </Section><Section id="_About"><Title>More About Trastuzumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/42265">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.43">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a699019.html">Trastuzumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.44"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.45">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer">Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C1647">Find Clinical Trials for Trastuzumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2006-10-05</DateFirstPublished><DateLastModified>2024-12-20</DateLastModified></DrugInformationSummary>
